Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Reumatología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Aún no recluta
Fase 2
ClinicalTrials.gov
Randomised, Placebo-controlled, Double-blind, Parallel-group Phase II Study to Evaluate the Efficacy and Safety of Oral BI 3000202 in Patients With Moderate to Severe Systemic Lupus Erythematosus (SLE)
INTERVENTIONAL
Inicio: 7 de abr de 2026
ID: NCT07409181
Completado
Fase 2
ClinicalTrials.gov
A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Systemic Lupus Erythematosus
INTERVENTIONAL
Inicio: 26 de mar de 2019
ID: NCT03920267
Reclutando
Fase 1
ClinicalTrials.gov
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986326 in Adult Participants With Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic Lupus Erythematosus
INTERVENTIONAL
Inicio: 21 de sept de 2023
ID: NCT06013995
Completado
Fase 2
ClinicalTrials.gov
An Exploratory Phase 2, Randomized, Double-blind, Multicenter Study To Assess The Effects Of Tofacitinib (Cp-690,550) On Magnetic Resonance Imaging Endpoints, In Methotrexate Naive Subjects With Early Active Rheumatoid Arthritis
INTERVENTIONAL
Inicio: 1 de oct de 2010
ID: NCT01164579
Completado
Fase 3
ClinicalTrials.gov
EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS
INTERVENTIONAL
Inicio: 10 de may de 2018
ID: NCT03000439
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants With Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
INTERVENTIONAL
Inicio: 15 de dic de 2022
ID: NCT05581199
Terminado
Fase 2
ClinicalTrials.gov
VELVET (Veltuzumab Various Doses Exploratory Trial), a Randomized, Double Blind, Placebo Controlled, Multicentre, Multinational Phase II Dose Range Finding Trial in Subjects With Moderate to Severe Rheumatoid Arthritis Insufficiently Controlled With Either Methotrexate Alone or Methotrexate Plus Anti-tumour Necrosis Factor Biological Treatment, Comparing 3 Different Subcutaneous Dosages of Anti-CD20 Monoclonal Antibody Veltuzumab to Placebo as an add-on Therapy to Methotrexate.
INTERVENTIONAL
Inicio: 1 de ago de 2011
ID: NCT01390545
Completado
Fase 3
ClinicalTrials.gov
Multicentric Evaluator-blinded Randomized Non-inferiority Study, to Asses the Compared Efficacy, Safety and Immunogenicity of Enerceptan® With Enbrel® in Combination With Methotrexate for the Treatment of Patients With Rheumatoid Arthritis
INTERVENTIONAL
Inicio: 1 de feb de 2016
ID: NCT03332719
Completado
Fase 1
ClinicalTrials.gov
A Randomized, Subject and Investigator-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Intravenously Administered Doses of PD-0360324 in Patients With Rheumatoid Arthritis Receiving Methotrexate
INTERVENTIONAL
Inicio: 1 de ago de 2007
ID: NCT00550355
Desconocido
ClinicalTrials.gov
NATIONAL VACCINATION REGISTRY FOR SARS-CoV-2 IN PATIENTS WITH RHEUMATIC DISEASES OF THE ARGENTINE SOCIETY OF RHEUMATOLOGY
OBSERVATIONAL
Inicio: 1 de jul de 2021
ID: NCT04845997
Activo, no recluta
Fase 3
ClinicalTrials.gov
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
INTERVENTIONAL
Inicio: 13 de abr de 2021
ID: NCT04527380
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Adult Subjects With Moderate-to-Severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy
INTERVENTIONAL
Inicio: 13 de dic de 2022
ID: NCT05648500
Terminado
Fase 2
ClinicalTrials.gov
A Phase IIB, Multi-Dose, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo in the Treatment of Psoriatic Arthritis
INTERVENTIONAL
Inicio: 1 de nov de 2007
ID: NCT00534313
Completado
Fase 1
ClinicalTrials.gov
Long-Term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Polyarticular-Course and Systemic Juvenile Idiopathic Arthritis
INTERVENTIONAL
Inicio: 16 de jul de 2014
ID: NCT02165345
Terminado
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients With Moderate to Severe Rheumatoid Arthritis (RA) Who Had an Inadequate Response to One or More TNF-α Inhibitors (FLEX V)
INTERVENTIONAL
Inicio: 1 de ene de 2011
ID: NCT01202773
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
INTERVENTIONAL
Inicio: 1 de nov de 2012
ID: NCT01711359
Completado
Fase 3
ClinicalTrials.gov
Phase 3 Randomized, Double-blind Study Of The Efficacy And Safety Of 2 Doses Of Cp-690,550 Compared To Methotrexate In Methotrexate Navie Patients With Rheumatoid Arthritis
INTERVENTIONAL
Inicio: 1 de ene de 2010
ID: NCT01039688
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects With Systemic Lupus Erythematosus (SLE)
INTERVENTIONAL
Inicio: 16 de nov de 2011
ID: NCT01484496
Completado
ClinicalTrials.gov
A Global Comparative Observational Study In Rheumatoid Arthritis (RA) Patients Who Are Treated With A TNF Inhibitor Or Tocilizumab As The First Biologic Therapy
OBSERVATIONAL
Inicio: 1 de feb de 2012
ID: NCT01543503
Reclutando
Fase 3
ClinicalTrials.gov
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
INTERVENTIONAL
Inicio: 12 de feb de 2020
ID: NCT04088396
Anterior
1
...
5
6
7
...
434
Siguiente
Filtros